The Molecular Basis of Predicting Druggability

Bioinformatics-From Genomes to Therapies

Volumn 3, Issue , 2008, Pages 1315-1334

  Al Lazikani, Bissan ^a   Gaulton, Anna ^b   Paolini, Gaia ^b   Lanfear, Jerry ^b   Overington, John ^a   Hopkins, Andrew ^b  

^a Inpharmatica Ltd   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Coworkers; Inhibitory; Inpharmatica; Lampel; Transmembrane

Indexed keywords

EID: 73649087500     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527619368.ch36     Document Type: Chapter

References (36)

1. AJAY, A., W. P.WALTERS AND M. A. MURCKO. 1998. Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? J. Med. Chem. 41: 3314-24.
2. ARLINGTON, S., S. BARNETT, S. HUGHES AND J. PALO. 2002. Pharma 2010: The Threshold of Innovation. IBM Business Consulting Services, London.
3. CONSORTIUM, G. O. 2001. Creating the gene ontology resource: design and implementation. Genome Res. 11: 1425-33.
4. DAVIES, K. 2002. Cracking the "druggable genome". Bio-IT World: http://www.bioitworld.com/archive/100902/firstbase.html.
5. DREWS, J. 2000. Drug discovery: a historical perspective. Science 287: 1960-4.
6. DREWS, J. 1996. Genomic sciences and the medicine of tomorrow. Nat. Biotechnol. 14: 1516-8.
7. DREWS, J. AND S. RYSER. 1997. Classic drug targets. Nat. Biotechnol. 15: 1318-9.
8. EGAN, W. J., W. P. WALTERS AND M. A. MURCKO. 2002. Guiding molecules towards drug-likeness. Curr. Opin. Drug Discov. Dev. 5: 540-9.
9. ERTL, P., B. ROHDE AND P. SELZER. 2000. Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 43: 3714-7.
10. GOLDEN, J. 2003. Towards a tractable genome: knowledge management in drug discovery. Curr. Drug Discov. 3(2): 17-20.
11. GOLDEN, J. B. 2003. Prioritizing the human genome: knowledge management for drug discovery. Curr. Opin. Drug Discov. Dev. 6: 310-6.
12. HAJDUK, P. J., J. R. HUTH AND S. W. FESIK. 2005. Druggability indices for protein targets derived from NMR-based screening data. J. Med. Chem. 48: 2518-25.
13. HOPKINS, A. L. AND C. R. GROOM. 2002. The druggable genome. Nat. Rev. Drug Discov. 1: 727-730.
14. HOPKINS, A. L. AND C. R. GROOM. 2003. Target analysis: a priori assessment of druggability. Ernst Schering Res. Found. Workshop 42: 11-7.
15. KUNTZ, I. D., K. CHEN, K. A. SHARP AND P. A. KOLLMAN. 1999. The maximal affinity of ligands. Proc. Natl Acad. Sci. USA. 96: 9997-10002.
16. LAJINESS, M. S., M. VIETH AND J. ERICKSON. 2004. Molecular properties that influence oral drug-like behavior. Curr. Opin. Drug Discov. Dev. 7: 470-7.
17. LANDER, E., L.M. LINTON, B. BIRREN, et al. 2001. Initial sequencing and analysis of the human genome. Nature 409: 860-921.
18. LIPINSKI, C. A. 2000. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44: 3-25.
19. LIPINSKI, C. A., F. LOMBARDO, B. W. DOMINY AND P. J. FEENEY. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. 23: 3-25.
20. MUEGGE, I. 2003. Selection criteria for drug-like compounds. Med. Res. Rev. 23:302-21.
21. MUEGGE, I., S. L. HEALD AND D. BRITTELLI. 2001. Simple selection criteria for drug-like chemical matter. J. Med. Chem. 44: 1841-6.
22. MURZIN, A. G., S. E. BRENNER, T. HUBBARD AND C. CHOTHIA. 1995. SCOP: a structural classification of proteins database for the investigation of sequences and structures. J. Mol. Biol. 274: 536-40.
23. ORTH, A. P., S. BATALOV, M. PERRONE AND S. K. CHANDA. 2004. The promise of genomics to identify novel therapeutic targets. Expert Opin. Ther. Targets 8: 587-96.
24. OVERINGTON, J. 2002. Prioritizing the proteome: identifying pharmaceutically relevant targets. Drug Discov. Today 7:516-21.
25. PAVLOU, A. K. AND J. M. REICHERT. 2004. Recombinant protein therapeutics-success rates, market trends and values to 2010. Nat. Biotechnol. 22: 1513-9.
26. PODLOGAR, B. L., I. MUEGGE AND L. J. BRICE. 2001. Computational methods to estimate drug development parameters. Curr. Opin. Drug Discov. Dev. 4: 102-9.
27. PROUDFOOT, J. R. 2002. Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. Bioorg. Med. Chem. Lett. 12: 1647-50.
28. REICHERT, J. M. 2005. Protein therapeutic success rates increase with biotech advances. Tufts Center for the Study of Drug Development Impact Report 7.
29. RUSS, A. P. AND S. LAMPEL. 2005. The Druggable Genome: an update. Drug Discov. Today 10(23-24): 1607-10.
30. VEBER, D. F., S. R. JOHNSON, H. Y. CHENG, B. R. SMITH, K. W. WARD AND K. KOPPLE. 2002. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45: 2615-23.
31. VENTER, J. C., M. D. ADAMS, E.W. MYERS, et al. 2001. The sequence of the human genome. Science 291(5507): 1304-51.
32. VIETH, M., M. G. SIEGEL, R. E. HIGGS, I. A. WATSON, D. H. ROBERTSON, K. A. SAVIN, G. L. DURST AND P. A. HIPSKIND. 2004. Characteristic physical properties and structural fragments of marketed oral drugs. J. Med. Chem. 47:224-32.
33. WALTERS, W. P., AJAY AND M. A. MURCKO. 1999. Recognizing molecules with drug-like properties. Curr. Opin. Chem. Biol. 3: 384-7.
34. WALTERS, W. P. AND M. A. MURCKO. 2002. Prediction of "drug-likeness". Adv. Drug Deliv. Rev. 54: 255-71.
35. WANG, J. AND K. RAMNARAYAN. 1999. Towards designing drug-like libraries: a novel computational approach for prediction of drug feasibility of compounds. J. Comb. Chem. 1: 524-33.
36. WINDHOVEN. 2005. Know they R&D enemy: the key to fighting attrition. In Vivo 19(1): 59.